Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins.

Akache B, Deschatelets L, Harrison BA, Dudani R, Stark FC, Jia Y, Landi A, Law JLM, Logan M, Hockman D, Kundu J, Tyrrell DL, Krishnan L, Houghton M, McCluskie MJ.

Vaccines (Basel). 2019 Dec 3;7(4). pii: E204. doi: 10.3390/vaccines7040204.

2.

Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma.

Stark FC, Agbayani G, Sandhu JK, Akache B, McPherson C, Deschatelets L, Dudani R, Hewitt M, Jia Y, Krishnan L, McCluskie MJ.

Biomedicines. 2019 Nov 23;7(4). pii: E91. doi: 10.3390/biomedicines7040091.

3.

Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.

Stark FC, Akache B, Ponce A, Dudani R, Deschatelets L, Jia Y, Sauvageau J, Williams D, Jamshidi MP, Agbayani G, Wachholz K, Harrison BA, Li X, Krishnan L, Chen W, McCluskie MJ.

Vaccine. 2019 Nov 8;37(47):7108-7116. doi: 10.1016/j.vaccine.2019.07.010. Epub 2019 Aug 2.

4.

A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.

Jia Y, Akache B, Deschatelets L, Qian H, Dudani R, Harrison BA, Stark FC, Chandan V, Jamshidi MP, Krishnan L, McCluskie MJ.

Int J Pharm. 2019 Apr 20;561:187-196. doi: 10.1016/j.ijpharm.2019.02.041. Epub 2019 Mar 2.

PMID:
30836154
5.

Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.

Akache B, Stark FC, Jia Y, Deschatelets L, Dudani R, Harrison BA, Agbayani G, Williams D, Jamshidi MP, Krishnan L, McCluskie MJ.

PLoS One. 2018 Dec 4;13(12):e0208067. doi: 10.1371/journal.pone.0208067. eCollection 2018.

6.

An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.

Stark FC, Weeratna RD, Deschatelets L, Gurnani K, Dudani R, McCluskie MJ, Krishnan L.

Vaccines (Basel). 2017 Oct 26;5(4). pii: E38. doi: 10.3390/vaccines5040038.

7.

In vitro evaluation of archaeosome vehicles for transdermal vaccine delivery.

Jia Y, McCluskie MJ, Zhang D, Monette R, Iqbal U, Moreno M, Sauvageau J, Williams D, Deschatelets L, Jakubek ZJ, Krishnan L.

J Liposome Res. 2018 Dec;28(4):305-314. doi: 10.1080/08982104.2017.1376683. Epub 2017 Sep 26.

PMID:
28948854
8.

Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.

McCluskie MJ, Deschatelets L, Krishnan L.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2772-2779. doi: 10.1080/21645515.2017.1316912. Epub 2017 May 24.

9.

Cell surface glycoproteins from Thermoplasma acidophilum are modified with an N-linked glycan containing 6-C-sulfofucose.

Vinogradov E, Deschatelets L, Lamoureux M, Patel GB, Tremblay TL, Robotham A, Goneau MF, Cummings-Lorbetskie C, Watson DC, Brisson JR, Kelly JF, Gilbert M.

Glycobiology. 2012 Sep;22(9):1256-67. doi: 10.1093/glycob/cws094. Epub 2012 Jun 12.

PMID:
22692048
10.

Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.

Krishnan L, Deschatelets L, Stark FC, Gurnani K, Sprott GD.

Clin Dev Immunol. 2010;2010:578432. doi: 10.1155/2010/578432. Epub 2011 Jan 18.

11.

Safety of archaeosome adjuvants evaluated in a mouse model.

Patel GB, Omri A, Deschatelets L, Sprott GD.

J Liposome Res. 2002 Nov;12(4):353-72.

PMID:
12519630

Supplemental Content

Loading ...
Support Center